{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:46:37Z","timestamp":1792511197540,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014549","name":"Stanford Cancer Institute","doi-asserted-by":"publisher","award":["SPO# 162509"],"award-info":[{"award-number":["SPO# 162509"]}],"id":[{"id":"10.13039\/100014549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["H2020; no. 101030481"],"award-info":[{"award-number":["H2020; no. 101030481"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xcrm.2026.103109","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:16:36Z","timestamp":1791558996000},"page":"103109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatially tuned localization of interleukins and OX40 agonists enhances synergistic anti-tumor immunity"],"prefix":"10.1016","volume":"7","author":[{"given":"John H.","family":"Klich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Nejatfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily L.","family":"Meany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben S.","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna D.","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2301-7126","authenticated-orcid":false,"given":"Eric A.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103109_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.xcrm.2026.103109_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103109_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103109_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.xcrm.2026.103109_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.xcrm.2026.103109_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","article-title":"Antagonists of PD-1 and PD-L1 in Cancer Treatment","volume":"42","author":"Lipson","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103109_bib7","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.103109_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold Tumors: A Therapeutic Challenge for Immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103109_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17425247.2022.2084070","article-title":"Intratumorally anchored cytokine therapy","volume":"19","author":"Wittrup","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.xcrm.2026.103109_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103109_bib11","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103109_bib12","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/1078-0432.CCR-03-0304","article-title":"Intratumoral Administration of Recombinant Human Interleukin 12 in Head and Neck Squamous Cell Carcinoma Patients Elicits a T-Helper 1 Profile in the Locoregional Lymph Nodes","volume":"10","author":"van Herpen","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103109_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41551-021-00831-9","article-title":"Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity","volume":"6","author":"Agarwal","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xcrm.2026.103109_bib14","volume":"119","author":"Lutz","year":"2022"},{"key":"10.1016\/j.xcrm.2026.103109_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2614","article-title":"Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy","volume":"11","author":"Momin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103109_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xcrm.2026.103109_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.chembiol.2021.10.012","article-title":"Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression","volume":"29","author":"Miller","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.xcrm.2026.103109_bib18","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1038\/s41467-023-40312-y","article-title":"Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103109_bib19","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.1021\/acs.chemrev.0c01177","article-title":"Translational Applications of Hydrogels","volume":"121","author":"Correa","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.xcrm.2026.103109_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn8264","article-title":"Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors","volume":"8","author":"Grosskopf","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.103109_bib21","doi-asserted-by":"crossref","first-page":"14877","DOI":"10.1021\/acsnano.3c08425","article-title":"Syringeable Near-Infrared Light-Activated In Situ Immunogenic Hydrogel Boosts the Cancer-Immunity Cycle to Enhance Anticancer Immunity","volume":"18","author":"Fu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.xcrm.2026.103109_bib22","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10555-024-10184-9","article-title":"OX40\/OX40 ligand and its role in precision immune oncology","volume":"43","author":"Thapa","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.xcrm.2026.103109_bib23","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI64859","article-title":"Depleting tumor-specific Tregs at a single site eradicates disseminated tumors","volume":"123","author":"Marabelle","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103109_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103109_bib25","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-21-1382","article-title":"Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer","volume":"82","author":"Hong","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103109_bib26","article-title":"Injectable Nanoparticle-Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies","volume":"9","author":"Correa","year":"2022","journal-title":"Adv. Sci. (Weinh)."},{"key":"10.1016\/j.xcrm.2026.103109_bib27","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/pol.20210652","article-title":"Gelation and yielding behavior of polymer\u2013nanoparticle hydrogels","volume":"59","author":"Grosskopf","year":"2021","journal-title":"J. Polym. Sci."},{"key":"10.1016\/j.xcrm.2026.103109_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202000295","article-title":"A Quantitative Description for Designing the Extrudability of Shear-Thinning Physical Hydrogels","volume":"21","author":"Lopez Hernandez","year":"2021","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.xcrm.2026.103109_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202203402","article-title":"Yield-Stress and Creep Control Depot Formation and Persistence of Injectable Hydrogels Following Subcutaneous Administration","volume":"32","author":"Jons","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.xcrm.2026.103109_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2026.103109_bib31","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.103109_bib32","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103109_bib33","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103109_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103109_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","article-title":"Memory T cells: strategies for optimizing tumor immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.xcrm.2026.103109_bib36","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood-2008-07-170274","article-title":"T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy","volume":"113","author":"Houot","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.103109_bib37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.103109_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cas.15195","article-title":"Circulating na\u00efve and effector memory T cells correlate with prognosis in head and neck squamous cell carcinoma","volume":"113","author":"Takahashi","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2026.103109_bib39","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.4049\/jimmunol.165.6.3043","article-title":"The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion1","volume":"165","author":"Gramaglia","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.103109_bib40","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.4049\/jimmunol.161.12.6510","article-title":"Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses","volume":"161","author":"Gramaglia","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.103109_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1084\/jem.188.2.297","article-title":"CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1","volume":"188","author":"Flynn","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.103109_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/4508794","article-title":"Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates","volume":"2019","author":"Sambi","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.xcrm.2026.103109_bib43","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.103109_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.103109_bib45","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.4049\/jimmunol.175.7.4677","article-title":"Recall Proliferation Potential of Memory CD8+ T Cells and Antiviral Protection1","volume":"175","author":"Bachmann","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.103109_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103109_bib47","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic Immunity Is Required for Effective Cancer Immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103109_bib48","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","article-title":"Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front","volume":"182","author":"Sch\u00fcrch","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103109_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1399-0039.2008.01088.x","article-title":"Memory T cells in cancer immunotherapy: which CD8+ T-cell population provides the best protection against tumours?","volume":"72","author":"Perret","year":"2008","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.xcrm.2026.103109_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ni889","article-title":"Lineage relationship and protective immunity of memory CD8 T cell subsets","volume":"4","author":"Wherry","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.103109_bib51","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1021\/acscentsci.0c00732","article-title":"Injectable Hydrogels for Sustained Codelivery of Subunit Vaccines Enhance Humoral Immunity","volume":"6","author":"Roth","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.xcrm.2026.103109_bib52","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1038\/ncomms7295","article-title":"Self-assembled hydrogels utilizing polymer\u2013nanoparticle interactions","volume":"6","author":"Appel","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103109_bib53","first-page":"3039","article-title":"Transport of molecules in the tumor interstitium: a review","volume":"47","author":"Jain","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103109_bib54","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1038\/s41598-023-33651-9","article-title":"Non-invasive imaging of interstitial fluid transport parameters in solid tumors in vivo","volume":"13","author":"Majumder","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:08:29Z","timestamp":1792508909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126005264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666379126005264"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103109","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatially tuned localization of interleukins and OX40 agonists enhances synergistic anti-tumor immunity","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103109"}}